Evidence map›Paper›PMID 42254818›Full record

ArticleAdvances in radiation oncology2026

Marcin Kubeczko, Berta Sousa, Francisco Oliveira, Cláudia Constantino, Catarina Duarte, Joana Castanheira, Leonor Matos, Justyna Kociołek, Michał Jarząb, Durval Costa and 4 more

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marcin KubeczkoBreast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Upper Silesia, Poland.
Berta SousaBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Francisco OliveiraNuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Cláudia ConstantinoNuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Catarina DuarteRadiotherapy Service, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Joana CastanheiraNuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Leonor MatosBreast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Justyna KociołekRadiotherapy Service, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Michał JarząbBreast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Upper Silesia, Poland.
Durval CostaNuclear Medicine-Radiopharmacology, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Fatima CardosoABC Global Alliance, Lisbon, Portugal.
Javier MoralesRadiotherapy Service, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Carlo GrecoRadiotherapy Service, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
Ana Luisa VasconcelosRadiotherapy Service, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Cyclin-dependent kinase (CDK) 4/6 inhibitors have transformed the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, yet resistance remains common. Metabolic response assessed by fluorine 18-labeled deoxyglucose might identify patients at risk of treatment failure earlier than conventional imaging. We evaluated the safety, feasibility, and efficacy of Methods and Materials: This retrospective study included 29 patients monitored with Results: Post-SBRT maximum standardized uptake value (SUV Conclusions:

Identifiers

PMID42254818
PMCPMC13234201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.